Retrospective analysis for thirty-nine patients with solitary fibrous tumor of pleura and review of the literature

World Journal of Surgical Oncology

Research

Hua-Liang Xiao¹  Yun-Ping Zhao²  Hui-Jun Niu²  Yao-Guang Jiang²  Wei Guo²  Zheng Ma²  Ru-Wen Wang² 

[1] Department of Pathology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Changjiang Route 10#, Chongqing, PR, China;Department of Thoracic Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Changjiang Route 10#, Chongqing, PR, China;

关键词: Solitary fibrous tumor;    Pleura;    Surgical treatment;    Prognosis;   

DOI  :  10.1186/1477-7819-9-134

 received in 2011-07-13, accepted in 2011-10-20,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundSolitary fibrous tumor of the pleura (SFTP) is an uncommon neoplasm arising from mesenchymal cells. The aim of this study is to summarize the experience and the outcome of the surgical treatment for 39 cases of SFTP.MethodsFrom January 2004 to December 2008, 39 patients underwent surgical resection of SFTP in our department. All patients had clinical follow-up by the same team of surgeons. The mean follow-up was 40.3 months.ResultsA local removal of the neoplasm was accomplished by video-assisted thoracic surgery (VATS) in 9 patients (group A) and by thoracotomy in 30 patients (group B) respectively. Comparing with group B, operations in group A took significantly less operative time, blood loss and spent less time in the intensive care unit and hospital. All specimens were positive for CD34 and Bcl-2. One patient developed recurrence, and the remaining 38 patients are alive and disease free at the end of follow-up.ConclusionsMalignant SFTP still had the potential recurrence. VATS represents the more acceptable choice for the selected patients with SFTP.

【 授权许可】

Unknown   
© Guo et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.